Spectral Medical's CMO Recognized as a World Expert in Sepsis; Supports World Sepsis Day and Sepsis Awareness Month

Spectral Sponsors Live Webinar hosted by its CMO at the Sepsis Alliance Symposium

September 13th is World Sepsis Day; September is designated as Sepsis Awareness Month

TORONTO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- **Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT)**, a late stage theranostic company advancing therapeutic options for sepsis and endotoxemic septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly owned subsidiary Dialco Medical Inc. ("Dialco"), today announced that Dr. John Kellum, Spectral's Chief Medical Officer, has been recognized as a World Expert in Sepsis by Expertscape.

Expertscape's PubMed-based algorithms place Dr. Kellum in the top 0.1% of scholars writing about Sepsis over the past 10 years, a level they label as "World Expert." Expertscape objectively ranks people and institutions by their expertise in more than 29,000 biomedical topics.

Additionally, 2021 is the 10th Anniversary of the Sepsis Alliance, the leading sepsis organization in the U.S. working to save lives and reduce suffering from sepsis. Sepsis Alliance is a charitable organization run by a dedicated team who share a strong commitment to battling sepsis. Spectral is honored to be a part of their journey of increasing awareness of sepsis to the public. Towards this end, Dr. Kellum will be presenting a live webinar entitled, "Precision Medicine for Sepsis: Targeted Therapy Based on Molecular Endotyping," at the Sepsis Alliance Symposium on September 30, 2021, at 2:00 p.m. ET. The webinar will focus on current methods used to identify sepsis subtypes and explore targeted therapies for such patients. Spectral Medical is sponsoring the webinar.

Spectral supports World Sepsis Day, which is September 13, 2021, as well as Sepsis Awareness Month, which is the month of September (#SAM2021).

About Spectral

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ("**PMX**"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 300,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year.

Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy ("**RRT**") across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market. Dialco is currently pursuing regulatory approval for U.S. in-home use of DIMI, which is based on the same RRT platform as SAMI, but will be intended for home hemodialysis use. DIMI recently received its FDA 510k clearance for use in hospital and clinical settings, and obtained its Health Canada license for use within Canadian hospitals, clinics and in home.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

Contact:

Mr. Chris Seto
CEO
Spectral Medical Inc.
416-626-3233 ext. 2004
cseto@spectraldx.com

Mr. Ali Mahdavi
Capital Markets & Investor Relations
Spinnaker Capital Markets Inc.
416-962-3300
am@spinnakercmi.com

David Waldman/Natalya Rudman
US Investor Relations
Crescendo Communications, LLC
212-671-1020
edt@crescendo-ir.com